Announcements Trials
Browse Landscape

Phase

Phase 2 1Phase 1/2 1

Status

Terminated 1Recruiting 1

Sponsor Class

OTHER 2

Study Type

Interventional 2

Sponsor

Cancer Type

Dermatologic 2

Conditions

Carcinoma, Non-Small-Cell Lung 4Neoplasms 3Lung Neoplasms 3Glioma 3Glioblastoma 3Nervous System Neoplasms 2Nervous System Diseases 2Multiple Myeloma 2Melanoma 2Central Nervous System Neoplasms 2Central Nervous System Diseases 2Breast Neoplasms 2Brain Neoplasms 2Brain Diseases 2Astrocytoma 2Unspecified Adult Solid Tumor, Protocol Specific 1Triple Negative Breast Neoplasms 1Sarcoma 1Resectable Pancreatic Cancer 1Resectable Esophageal Cancer 1Radiation Pneumonitis 1Precursor Cell Lymphoblastic Leukemia-Lymphoma 1Pleural Mesothelial Neoplasm 1Neoplasm Metastasis 1Lymphoma, Non-Hodgkin 1Lymphoma, Mantle-Cell 1Lymphoma, Large-Cell, Immunoblastic 1Lymphoma, Large B-Cell, Diffuse 1Lymphoma, Follicular 1Lymphoma, B-Cell, Marginal Zone 1

Interventions

pembrolizumab 287Nivolumab 258Ipilimumab 236Cyclophosphamide 135aldesleukin 134Interleukin-2 104Temozolomide 75Dacarbazine 74trametinib 70Vemurafenib 69fludarabine 68dabrafenib 65fludarabine phosphate 62sargramostim 44binimetinib 44Radiosurgery 44Biopsy 43Paclitaxel 42Bevacizumab 42incomplete Freund's adjuvant 39encorafenib 37Radiotherapy 36Cisplatin 36CTLA-4 Antigen 36atezolizumab 35Carboplatin 35Magnetic Resonance Spectroscopy 33cobimetinib 32Specimen Handling 30Introns 30

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
Interventional × Melanoma × Adjuvants, Immunologic × Clear all
NCT04594187 2026-02-17

MelPORT

M.D. Anderson Cancer Center

Phase 2 Recruiting
168 enrolled
Dermatologic

Melanoma

NCT00365937 2019-03-06

Immunization of Disease-Free Melanoma Patients With Different HLA-A2 Peptides

Cliniques universitaires Saint-Luc- Université Catholique de Louvain

Phase 1/2 Terminated
19 enrolled
Dermatologic

Melanoma

Data powered by HemOnc (CC BY 4.0) Colophon âš¡